|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-9-22
|
|
pubmed:abstractText |
XAGE-1b is regarded as one of the most immunogenic antigens and the most promising targets for lung adenocarcinoma immunotherapy. In this study, we sought to determine whether monocyte-derived dendritic cells (DCs) pulsed with purified full-length XAGE-1b could induce specific cytotoxic T lymphocytes (CTLs) against tumour cells from patients with non-small cell lung cancer (NSCLC) in vitro. XAGE-1b mRNA expression was examined in primary cultures of lung cancer cells and normal lung epithelial cells established from fresh tissues surgically resected from 30 patients with NSCLC using reverse transcription-polymerase chain reaction (RT-PCR). XAGE-1b mRNA expression was observed in 11 of 18 (61.1%) adenocarcinomas and one of 12 (8.3%) lung cancers of other histological types (P = 0.015). The 246-base pairs XAGE-1b gene was inserted into a recombinant expression vector. Full-length XAGE-1b was then expressed in BL21 (DE3) Escherichia coli and purified by AKTA-fast performance liquid chromatography (FPLC). DCs generated from peripheral blood mononuclear cells were pulsed with XAGE-1b by incubation with the protein at an immature stage. The XAGE-1b-pulsed DCs induced CTLs following 14 days of co-culture. Finally, an adherent target detachment (ATD) assay was performed to test the cytotoxicity of the XAGE-1b-specific CTLs against cancer cells and normal lung epithelial cells. The XAGE-1b-specific CTLs had a stronger lytic effect on autologous XAGE-1b mRNA-positive cancer cells than on autologous XAGE-1b mRNA-negative cancer cells or allogenous XAGE-1b mRNA-positive cancer cells. The CTLs had no lytic activity against normal lung epithelial cells. These results can be used to develop simple and effective cancer/testis antigen-based immunotherapies for NSCLC.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-10197611,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-10987281,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-11205900,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-11938454,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-11992404,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-12445278,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-12479262,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-12747762,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-14696120,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-14738373,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-15252201,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-15627611,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-15699177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-15709203,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-16061866,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-16267030,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-16299236,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-17335148,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-17666327,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-1840703,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-8524854,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-9002667,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-9368778,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-9521319,
http://linkedlifedata.com/resource/pubmed/commentcorrection/18803763-9618514
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1365-2249
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
153
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
392-400
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18803763-Adenocarcinoma,
pubmed-meshheading:18803763-Antigens, Neoplasm,
pubmed-meshheading:18803763-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:18803763-China,
pubmed-meshheading:18803763-Dendritic Cells,
pubmed-meshheading:18803763-Flow Cytometry,
pubmed-meshheading:18803763-Fluorescent Antibody Technique,
pubmed-meshheading:18803763-Humans,
pubmed-meshheading:18803763-Lung Neoplasms,
pubmed-meshheading:18803763-RNA, Messenger,
pubmed-meshheading:18803763-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:18803763-T-Lymphocytes, Cytotoxic
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
A dendritic cell-based tumour vaccine for lung cancer: full-length XAGE-1b protein-pulsed dendritic cells induce specific cytotoxic T lymphocytes in vitro.
|
|
pubmed:affiliation |
Division of Pulmonary Oncology, Cancer Center and Lung Cancer Research Institute, Guangdong Provincial People's Hospital, Guangzhou, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
